- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03463304
Environmental Factors and the Gut Microbiome - Endocannabinoid Axis (eMECA)
The Influence of Host Environmental Factors on the Gut Microbiome - Endocannabinoid Axis in Metabolic and Mental Health
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The gut microbiome and the endocannabinoid system (ECS) could be interacting together and influence local enteric and peripheral metabolic functions and mental health.
The association of some host environmental factors (e.g. age, metabolic status, dietary habits) with gut microbiota composition and function has been investigated but, to our knowledge, little is known about their influence on the ECS.
There is also a need to better understand the influence of these factors and the interplay between the gut microbiota and the ECS and their relationship with intestinal, metabolic and mental health.
The investigators therefore propose to fill this knowledge-gap in the general population of adults with various body composition, dietary habits and daily physical activity levels.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Quebec
-
Québec, Quebec, Kanada, G1V 0A6
- Institut sur la nutrition et les aliments fonctionnels - INAF
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Computer and internet access
- Understanding of written French
Exclusion Criteria:
- Intestinal pathologies
- Pregnancy or breast-feeding
- Recent significant weight variations
- Recent completion of antibiotic treatment
- Alcohol consumption over sex-specific recommendations
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Ekologisk eller gemenskap
- Tidsperspektiv: Blivande
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Evaluation of the influence of dietary habits assessed via Food Frequency Questionnaire (FFQ) on the relationship between gut microbiota composition and circulating endocannabinoids
Tidsram: September 2018
|
FFQ items will be used to identify dietary habits by unsupervised clustering to evaluate their association with gut microbiota composition obtained from ribosomal RNA sequencing and plasma endocannabinoid (e.g.
Arachidonoylethanolamide, 2 arachidonoyl glycerol and their derivatives) concentrations.
|
September 2018
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Evaluation of the effect of adiposity assessed by Dual-energy X-ray Absorptiometry (DXA) scan on the relationship between gut microbiota composition and circulating endocannabinoids.
Tidsram: September 2018
|
The effect of adiposity measured by DXA scan on the relationship between gut microbiota composition and diversity obtained from ribosomal RNA sequencing and plasma endocannabinoids (e.g.
Arachidonoylethanolamide, 2 arachidonoyl glycerol and their derivatives) will be investigated.
|
September 2018
|
|
Evaluation of the effect of fasting glycemia on the relationship between gut microbiota composition and circulating endocannabinoids.
Tidsram: September 2018
|
The effect of fasting glycemia, used to infer metabolic status, on the relationship between gut microbiota composition and diversity obtained from ribosomal RNA sequencing and plasma endocannabinoids (e.g.
Arachidonoylethanolamide, 2 arachidonoyl glycerol and their derivatives) will be investigated.
|
September 2018
|
|
Evaluation of the effect of fasting triglyceridemia on the relationship between gut microbiota composition and circulating endocannabinoids.
Tidsram: September 2018
|
The effect of fasting triglyceridemia, used to infer metabolic status, on the relationship between gut microbiota composition and diversity obtained from ribosomal RNA sequencing and plasma endocannabinoids (e.g.
Arachidonoylethanolamide, 2 arachidonoyl glycerol and their derivatives) will be investigated.
|
September 2018
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Alain Veilleux, PhD, Laval University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2017-328
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Psykisk hälsa 1
-
Transcultural Psychosocial Organization NepalKing's College LondonRekryteringMental Health WellnessNepal
-
Hospital Miguel ServetAktiv, inte rekryterandeMental Health WellnessSpanien
-
Wake Forest University Health SciencesAvslutad
-
Fonterra Research CentreSun GenomicsAvslutad
-
City University of Hong KongStanford University; Harvard UniversityAvslutadMental Health WellnessColombia, Indonesien, Sydafrika, Ukraina
-
Fonterra Research CentreAvslutadMental Health WellnessFörenta staterna
-
Chinese University of Hong KongOkänd
-
Hospital Miguel ServetAvslutad
-
Hospital Miguel ServetAvslutadMental Health WellnessSpanien
-
Universidad Nacional de Educación a DistanciaUniversidad Rey Juan Carlos; Ministerio de Ciencia e Innovación, SpainAvslutadMental Health WellnessSpanien